Pharmanutra S.p.A. Announces 2026 STAR Conference

The company reports another year of double-digit growth, with strong performance from new business units in the U.S. and China.

Mar. 24, 2026 at 7:24am

Got story updates? Submit your updates here. ›

Pharmanutra S.p.A., a developer and marketer of scientifically advanced nutraceuticals and medical devices, has announced its 2026 STAR Conference to be held in Milan on March 24-25, 2026. The company reported another year of double-digit growth, with foreign markets up 23.2% and the domestic market up 9.2%. New business units in the U.S. and China also saw remarkable performance, with the U.S. unit achieving 1.6% market share and the China unit ranking #2 on TMG in the iron supplements category.

Why it matters

Pharmanutra's continued growth and expansion into new markets, as well as its focus on scientific innovation, demonstrate the company's ability to capitalize on trends in the nutraceutical and medical device industries. The performance of the new business units in the U.S. and China also highlights the company's strategic approach to global expansion.

The details

Pharmanutra reported net sales revenues of €131.7 million, up 14% from the previous year, with EBITDA of €34.2 million, a 10% increase. The company's net result was €20 million, a 20% increase. Pharmanutra's new business units in the U.S. and China also saw strong performance, with the U.S. unit achieving 1.6% market share and the China unit ranking #2 on TMG in the iron supplements category. The company also announced plans to expand its product range in the U.S. and China, as well as obtain FDA registration and AEO (Full) status in the U.S.

  • The 2026 STAR Conference will be held on March 24-25, 2026 in Milan.
  • Pharmanutra reported its financial results for the fiscal year 2025.
  • The company's U.S. unit achieved a 1.6% market share by early March 2026.
  • Pharmanutra's China unit ranked #2 on TMG in the iron supplements category as of March 2026.
  • The company plans to expand its product range in the U.S. and China in Q3 2026 and Q1 2027.

The players

Pharmanutra S.p.A.

A developer and marketer of scientifically advanced nutraceuticals and medical devices, founded in 2003 and operating in 80 countries with 52 partners.

Pharmanutra U.S. Corp.

Pharmanutra's U.S. subsidiary, focused on digital marketing and e-commerce, which achieved 1.6% market share by early March 2026.

Pharmanutra Espana

Pharmanutra's Spanish subsidiary.

Akern

A company acquired by Pharmanutra in 2022, focused on research and development of bioimpedance medical devices and software for body composition analysis.

Pharmanutra China Cross Border E-Commerce

Pharmanutra's Chinese subsidiary, which has a strong presence on five online platforms and ranked #2 on TMG in the iron supplements category as of March 2026.

Got photos? Submit your photos here. ›

What they’re saying

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

Pharmanutra plans to expand its product range in the U.S. and China, with 3 new SKUs scheduled for launch in Q3 2026 and 4 additional SKUs in Q1 2027. The company also plans to obtain FDA registration and AEO (Full) status in the U.S. in the near future.

The takeaway

Pharmanutra's strong financial performance, successful expansion into new markets, and focus on scientific innovation position the company for continued growth and leadership in the nutraceutical and medical device industries. The company's ability to adapt to changing market conditions and consumer preferences, as well as its commitment to quality and research, are key factors in its success.